Search

The article explores the differences between smooth muscle cells and fibroblasts in the proximal thoracic aorta based on their embryonic origins in response to Angiotensin II. The study found that while both cell types exhibited transcriptomic changes when exposed to Angiotensin II, the differences between cells derived from different embryonic origins were minimal. Interestingly, a new sub-population of fibroblasts emerged in response to Angiotensin II, showing lineage-specific differences in extracellular matrix-related genes. This research sheds light on the complex interplay between cell origins and responses to Angiotensin II in the pre-pathological phase of thoracic aortopathy. [Extracted from the article]

The article explores the effects of ligand binding on the activation of the Type-2 Angiotensin II receptor, a key player in cardiovascular regulation. Through molecular dynamics simulations, researchers found that Angiotensin II stabilizes the active state of the receptor, while Angiotensin 1-7 enhances flexibility in the inactive state. The study sheds light on the distinct roles of these ligands in regulating receptor dynamics, offering potential therapeutic opportunities for cardiovascular diseases. [Extracted from the article]

A study conducted in Tamil Nadu, India, focused on the stability assessment of Azelnidipine and Telmisartan in a combined tablet formulation using HPTLC. The research developed a new HPTLC approach that proved to be simple, quick, precise, selective, and accurate in assessing the stability of the drugs. The study found that the drugs degraded in acidic, basic, oxidative, and heat environments but remained stable in light or neutral environments, providing valuable insights for drug strength and stability assessment. [Extracted from the article]

A recent study conducted at the Universidad Autonoma de Madrid explored the effects of supplementation with standardized green/black or white tea extracts on hypertension and ischemia-reperfusion-induced myocardial damage in mice. The research found that both tea extracts exhibited anti-inflammatory and antioxidant effects in arterial tissue, reducing endothelial dysfunction and cardiovascular damage induced by angiotensin II infusion. While both extracts showed beneficial effects, supplementation with the tea complex (CTE) also significantly reduced systolic blood pressure and exerted antihypertensive effects, potentially supporting cardiovascular health. This study provides valuable insights into the potential benefits of tea extracts in mitigating cardiovascular damage and hypertension. [Extracted from the article]

Researchers from the Cleveland Clinic have implemented a pharmacy referral protocol for patients taking sacubitril/valsartan to improve adherence to treatment. The protocol aims to provide adherence services to patients with heart failure, potentially leading to clinical and nonclinical benefits such as cost savings. The study found that medication-specific workflows could be a feasible option for pharmacies to ensure the offering of adherence services to patients with high-risk disease states. This research was published in the Journal of Managed Care & Specialty Pharmacy and has been peer-reviewed. [Extracted from the article]

Researchers from the University of Valencia conducted a study on the effects of Sodium Valproate on aortic hypercontractility in rabbits with acute myocardial infarction (AMI). The study found that Sodium Valproate reversed the increased vasoconstriction caused by AMI by modulating the sympathetic nervous system, endothelin 1, and angiotensin II in the aorta. This research suggests that Sodium Valproate could be a promising candidate for the treatment of AMI due to its vascular and cardioprotective effects. The study was funded by various organizations, including the Ministry of Universities in Spain and the European Recovery, Transformation, and Resilience Plan. [Extracted from the article]

A recent study from Chonnam National University Medical School in South Korea explores the relationship between chronic kidney disease (CKD) and hypertension, highlighting the role of peroxiredoxin 5 (Prdx5) in kidney fibrosis. The research suggests that Prdx5 acts as a negative regulator of the sodium-chloride cotransporter, potentially offering insights into antihypertensive drug development. This study sheds light on the intricate mechanisms underlying CKD-related hypertension and the potential therapeutic implications of targeting Prdx5. [Extracted from the article]

Researchers at the University of Sao Paulo conducted a study on aging nephropathy, focusing on the role of intrarenal angiotensin II and the NF-kappa B pathway in chronic kidney disease progression. The study involved adult male rats treated with losartan and a NF-kappa B inhibitor, showing promising results in preventing renal abnormalities associated with aging. The research suggests that simultaneous blockade of renal AngII and inhibition of the NF-kappa B pathway could be a novel approach to slowing the decline of renal function with age. [Extracted from the article]

Researchers at Southeast University School of Medicine in China conducted a study on the therapeutic role of miR-26a in cardiorenal injury in a mice model of chronic kidney disease induced by angiotensin-II. The study found that miR-26a plays a crucial role in regulating the LIMS1/ILK signaling pathway, which is a common mechanism in heart and kidney tissues affected by chronic kidney disease. The findings suggest that miR-26a could be a potential target for treating cardiorenal injury in chronic kidney disease. [Extracted from the article]

A study conducted at the Naval Medical Center of PLA explored the role of the Janus Kinase 2/Signal Transducer and Activator of Transcription 3/Cyclooxygenase 2 signaling pathway in mediating the effects of central Angiotensin II on hypertension. The research found that central Angiotensin II induces the accumulation of prostaglandin E2 in the rostral ventrolateral medulla, leading to increased oxidative stress and sympathetic outflow, contributing to essential hypertension. This study sheds light on the molecular mechanisms underlying hypertension and potential therapeutic targets for cardiovascular diseases. [Extracted from the article]

Researchers at Afe Babalola University conducted a study on left ventricular hypertrophy (LVH) in young hypertensives, focusing on the potential role of mTOR and angiotensin-II as pathogenic markers. The study involved 110 hypertensive and 60 normotensive participants aged 18-45, with findings indicating a prevalence of LVH among hypertensive individuals. The research suggested an interaction between mTOR and Ang II in LVH development, highlighting associations with dyslipidemia, inflammation, and fibrosis. The study was published in BMC Cardiovascular Disorders and can be accessed for further information. [Extracted from the article]

Researchers at the University of Washington conducted a study on aortic disease, focusing on the role of mitochondrial dysfunction in age-related hypertensive aortic disease. The study used a unique mouse model to test the development of aortic aneurysm in older mice treated with angiotensin II. The results showed an age-dependent increase in aortic size and unexpected changes in mitochondrial respiratory capacity associated with disease development. This research emphasizes the importance of studying age-related diseases in the context of aging biology. [Extracted from the article]

Researchers at Emory College of Arts and Sciences conducted a study on the effects of aging and Losartan, an angiotensin II type 1 receptor blocker, on the mitochondrial proteome in mice. The study found that aging led to a downregulation of certain proteins related to energy production, while Losartan treatment in older mice showed an upregulation of these proteins. The research suggests that Losartan may have the potential to compensate for age-related decline in mitochondrial function, offering a possible pharmacological intervention to reverse aging-related changes. The study was published in Innovation in Aging and can be accessed for free online. [Extracted from the article]

Researchers at Brigham and Women's Hospital in Boston, Massachusetts, have reported new data on hyperaldosteronism, focusing on sex differences in salt-sensitive blood pressure. The study found that women have higher salt-sensitive blood pressure and aldosterone levels compared to men, suggesting a relative hyperaldosteronism state in women. However, men had higher sedentary aldosterone levels. The research, funded by the National Institutes of Health and Charles A. King Trust, concluded that the sex differences in salt-sensitive blood pressure may be due to lower angiotensin II responsiveness in men and not necessarily relative hyperaldosteronism. [Extracted from the article]

Researchers from the Faculty of Medicine Osijek in Croatia conducted a study on the effects of angiotensin II (AngII) exposure on endothelial cells following high salt intake. The study found that AngII reduced reactive oxygen species production and modulated cell adhesion molecules' expression in human aortic endothelial cells. This research was funded by the Faculty of Medicine Osijek Institutional and the European Structural And Investment Funds through a grant from the Croatian National Science Center of Excellence For Personalized Health Care. For more information, the full article can be accessed at https://doi.org/10.3390/biomedicines12122741. [Extracted from the article]

A recent study conducted at Semmelweis University in Budapest, Hungary, focused on the direct vascular effects of the peptide hormone angiotensin II (Ang II). The research highlighted the role of Ang II in controlling body fluids and blood pressure through smooth muscle contraction and vascular resistance. The study also emphasized the importance of Ang II in vascular pathologies and the potential benefits of AT1R antagonists and ACE inhibitors in inhibiting pathological wall remodeling. For more information, the full report can be accessed in the International Journal of Molecular Sciences. [Extracted from the article]

Researchers at New York Medical College conducted a study on the effects of maternal undernutrition-induced low birth weight on the development of high blood pressure and kidney disease in mice. The study found that aged low birth weight mice experienced renal oxidative stress, impaired vascular function, and altered sensitivity to angiotensin II, leading to increased blood pressure and decreased renal function. Pharmacological interventions targeting these factors improved vascular and renal function in the low birth weight mice. The research was supported by a National Institute of Health Grant and can be found in the Kidney and Blood Pressure Research journal. [Extracted from the article]

The article discusses a clinical trial, NCT06749418, focusing on the role of the mineralocorticoid receptor in microvascular endothelial dysfunction after preeclampsia. Women who had preeclampsia during pregnancy are at a higher risk of developing cardiovascular disease later in life, with an exaggerated vascular response to high-salt intake. The study aims to understand the mechanisms underlying this dysfunction by examining the role of the mineralocorticoid receptor in mediating microvascular dysfunction before and after a high-salt stimulus. The trial involves examining blood vessels in the skin to better understand microvascular dysfunction in these women. [Extracted from the article]

Researchers at "Victor Babes" University of Medicine and Pharmacy in Timisoara, Romania, conducted a study on olmesartan medoxomil therapy, a prodrug with antihypertensive and antioxidant properties. The study focused on improving the drug's solubility through a host-guest inclusion complex with heptakis(2,6-di-O-methyl)-b-cyclodextrin (DMbCD) and evaluating its compatibility with various pharmaceutical excipients. The research highlighted the potential of the olmesartan medoxomil/DMbCD inclusion complex for future pharmaceutical formulations, noting precautions regarding certain excipients at high temperatures. The study was published in Pharmaceutics and can be accessed for further information. [Extracted from the article]

A recent study conducted at Wake Forest University School of Medicine focused on sepsis and its association with high mortality rates. The research examined the renin-angiotensin-aldosterone system (RAAS) in sepsis patients and found that those with high renin concentrations exhibited altered levels of ACE, ACE2, DPP3, and angiotensinogen, potentially impacting the expected increase in Angiotensin II. This study sheds light on the complex interplay of RAAS components in sepsis patients with varying renin levels. For more information, the full article can be accessed for free at https://doi.org/10.1042/cs20242168. [Extracted from the article]

The article explores how Angiotensin II suppresses renin secretion by inducing synchronized calcium oscillations in juxtaglomerular (JG) cells within the kidney. These oscillations are driven by endoplasmic reticulum-derived calcium release, ORAI channels, and gap junctions, ultimately leading to suppressed renin secretion. The study aims to elucidate the role of cellular organization in calcium-mediated signaling and its impact on renin regulation within the juxtaglomerular apparatus (JGA). [Extracted from the article]

Research from Wuhan University in China explores the role of CircHelz in protecting against angiotensin II-induced cardiac fibrosis through miR-29b modulation. The study suggests that CircHelz inhibition could be a potential therapeutic strategy for cardiac fibrosis caused by angiotensin II. This research sheds light on the molecular mechanisms involved in cardiac fibrosis and highlights the potential for new treatment approaches in cardiovascular diseases. [Extracted from the article]

Researchers from Lewis Katz School of Medicine at Temple University conducted a study on abdominal aortic aneurysm induced by angiotensin II. They found that vascular smooth muscle cell signaling, specifically glucose transporter 1 (GLUT1), is not essential for the development of AAA in mice. The study concluded that VSMC GLUT1 is dispensable for AAA development induced by Ang II in mice. The research was funded by the National Institutes of Health and the National Institute on Aging. [Extracted from the article]

A recent study conducted at the Lady Davis Institute for Medical Research in Montreal, Canada, explored the role of Vg6/vd1+ Gd T cells in protecting mice from the effects of Angiotensin II on blood pressure and endothelial function. The research found that these specific T cells reduced the elevation of blood pressure and endothelial dysfunction induced by Angiotensin II infusion. The study was supported by various Canadian research institutions and has been peer-reviewed and published in the Journal of Hypertension. For more information, readers can contact the lead researcher, Ernesto L. Schiffrin, at the Lady Davis Institute for Medical Research in Montreal. [Extracted from the article]

A clinical trial, NCT06746753, aims to evaluate the benefits of exogenous Angiotensin II versus norepinephrine treatment in septic shock patients to improve outcomes. The trial focuses on determining better predictors of septic shock severity and aims to restore the renin-angiotensin-aldosterone system in sepsis. The study will provide insights into treatment regimens and may enhance patient care for those with septic shock. [Extracted from the article]

Researchers at Monaldi Hospital in Naples, Italy, conducted a study on the effects of angiotensin receptor neprilysin inhibitor (ARNI) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) on arrhythmic burden in patients with a failing systemic right ventricle (sRV). The study included 46 patients on sacubitril/valsartan therapy, with 50% also receiving dapagliflozin. After a median follow-up of 36 months, a significant reduction in clinically relevant atrial and ventricular arrhythmias was observed, suggesting that this therapy combination may offer antiarrhythmic effects in this patient population. [Extracted from the article]

A recent report from the University of California San Francisco (UCSF) discusses the dysregulation of the renin-angiotensin-aldosterone-system (RAAS) in sepsis and its potential impact on patient outcomes. The research highlights the use of exogenous angiotensin II as a new therapeutic agent in septic shock. A multinational expert panel provided guidance on patient selection and treatment options with exogenous angiotensin II, suggesting the need for further research in this area. [Extracted from the article]

Researchers have submitted a patent application for "ACE2-Targeted Compositions and Methods for Treating COVID-19" to address the urgent need for effective treatments against SARS-CoV-2. The invention involves a monoclonal antibody that specifically binds to human angiotensin converting enzyme 2 (hACE2) and inhibits the binding of the virus to hACE2. This patent application also includes methods for reducing the likelihood of infection and treating individuals with SARS-CoV-2 using the monoclonal antibody. The patent application was filed by Maddon Advisore LLC and inventor Paul J. Maddon from Scarsdale, New York, United States. [Extracted from the article]

Researchers at the University of Colorado Health have explored the use of vasoactive agents, specifically synthetic angiotensin-II (AT-II), in treating severe burn injuries and septic shock. While traditional therapies like catecholamines and vasopressin are commonly used, the potential benefits of synthetic AT-II in regulating blood pressure and improving clinical outcomes are being investigated. The study highlights the dysregulation of the renin-angiotensin-aldosterone system in burn and septic shock patients, emphasizing the need for further research in this area. [Extracted from the article]

A recent study conducted at the University of Mississippi Medical Center explored the role of renal medullary bilirubin and biliverdin reductase in Angiotensin II-dependent hypertension. The research found that increased circulating bilirubin can attenuate Angiotensin II-induced hypertension and improve renal hemodynamics. The study suggests that mechanisms enhancing bilirubin and biliverdin reductase in the renal medulla could be a promising approach to treating hypertension. [Extracted from the article]

The article discusses a study conducted by the Duke Clinical Research Institute on the implementation of guideline-directed medical therapy (GDMT) in heart failure patients after hospitalization. The study found that there is a significant gap in the use and titration of GDMT, with low usage rates that did not improve over a 12-month period. The researchers emphasized the importance of initiating GDMT during hospitalization to improve long-term medication adherence. The study involved 4646 participants and highlighted the need for better strategies to optimize patient care for heart failure. [Extracted from the article]

A study conducted at Southern Medical University in Guangdong, China, explored the role of Nuclear Receptor Subfamily 4 Group a Member 1 (Nur77) in easing oxidative stress induced by Angiotensin II in vascular smooth muscle cells (VSMCs) in hypertension. The research found that Nur77 suppressed cell growth, migration, and oxidative stress in VSMCs treated with Angiotensin II by promoting the transcription of NLRC3, which in turn repressed the TRAF6/NF-kappa B axis. This study provides new insights into the pathogenesis of hypertension. [Extracted from the article]

A study conducted by Osaka University Graduate School of Medicine focused on the potential of a vaccine targeting Fibroblast Activation Protein (FAP) to reduce cardiac fibrosis by eliminating myofibroblasts in mice. The research found that the FAP vaccine significantly decreased cardiac fibrosis and the accumulation of FAP-positive cells in the cardiac tissues of mice subjected to chronic cardiac stress. The study concluded that the FAP vaccine could be a therapeutic tool for cardiac fibrosis, showing no adverse effects in myocardial infarction and skin injury models. [Extracted from the article]

A recent study conducted at Cincinnati Children's Hospital and Medical Center focused on the impact of Angiotensin II signaling on cardiac fibrosis and diastolic dysfunction in mice with sickle cell anemia. The researchers found that blocking Angiotensin II receptor-I (ATR1) signaling with losartan led to improvements in cardiac parameters, diastolic function, and restrictive physiology in the mice. The study concluded that Angiotensin II signaling plays a crucial role in the development of cardiac fibrosis in sickle cell anemia patients, and its effects can be reversed by ATR1 blockade. [Extracted from the article]

A study from Mercer University School of Medicine explores the pathophysiology of heart failure, focusing on the role of angiotensin II-activated macrophages in cardiac remodeling and dysfunction. The research highlights the impact of angiotensin II on macrophages, leading to the release of inflammatory mediators and the development of hypertension, cardiac hypertrophy, and heart failure. The study discusses the challenges in translating these findings into treatments for heart failure patients. For more information, the full article is available in Cells journal. [Extracted from the article]

A recent study conducted by researchers at the Free University of Brussels (ULB) focused on vasopressor therapy in clinical medicine, particularly in intensive care patient management. The study highlighted the importance of tailoring therapy to individual patients and their hemodynamic response, emphasizing the need to avoid excessive vasoconstriction and consider different vasopressor agents based on the patient's condition. The preferred first-line agent, norepinephrine, was noted for its reliable vasoconstrictor effects and minimal impact on heart rate, while other vasoactive agents like vasopressin and angiotensin II were also discussed. The research concluded that dobutamine, along with continued fluid administration, could help maintain adequate tissue perfusion in patients with reduced oxygen delivery. [Extracted from the article]

Scienture Inc. has been issued a patent for Losartan liquid formulations and methods of use, which are used to treat hypertension and related conditions. Losartan is an angiotensin II receptor blocker that helps lower blood pressure and reduce the risk of stroke in patients with hypertension. The patent outlines specific pharmaceutical compositions and methods for administering Losartan orally, ensuring stability and effectiveness over time. This development aims to provide improved treatment options for individuals with hypertension and related cardiovascular conditions. [Extracted from the article]

Recent research from Beijing Xiaotangshan Hospital highlights the role of miR-378 in inhibiting angiotensin II-induced cardiomyocyte hypertrophy by targeting AKT2. The study emphasizes the potential of micro-ribonucleic acids (miRNAs) for early diagnosis and treatment of cardiomyocyte hypertrophy, which is crucial in heart failure development. The findings suggest that targeting the miR-378/AKT2 axis could offer therapeutic opportunities to alleviate cardiomyocyte hypertrophy. [Extracted from the article]

Johns Hopkins Medicine scientists have identified a potential reason why patients with Loeys-Dietz syndrome are prone to developing aneurysms at the root of the aorta. The study found that vascular smooth muscle cells in the aortic root of mice with this disorder produce excessive amounts of the critical protein Gata4, making them susceptible to aneurysms. Understanding the vulnerability of the aortic root in Loeys-Dietz syndrome may lead to improved treatment strategies for this condition and other vascular connective tissue disorders. [Extracted from the article]

A patent has been issued for compositions related to blood storage and transfusions by the Albert Einstein College of Medicine. The patent focuses on a transdermal formulation for delivering active agents to treat diseases associated with elevated CD38 levels and decreased NAD+ levels. The formulation aims to reduce inflammation, oxidative stress, and senescence in various disease states, including cardiovascular diseases, renal failure, osteoarthritis, lupus, neuropathies, and age-related decline. The patent also discusses methods for preparing blood samples with delayed onset of storage lesions in red blood cells and transfusing these samples to subjects in need. [Extracted from the article]

A patent has been issued for techniques related to the dysregulation of the trauma regulation pathway, focusing on addressing physiological conditions associated with this pathway. The patent discusses the activation and modulation of the renin-angiotensin system and local sensory neurons in response to wounds or traumatic injuries. It highlights the importance of maintaining the balance of this pathway to prevent inappropriate activation or lack of downregulation. The patent also includes methods for modulating immune responses in subjects by applying ultrasound energy to internal tissues and measuring changes in circulating biomarkers. [Extracted from the article]

A recent study from the University of North Carolina highlights the role of oxidative stress, inflammation, and the renin-angiotensin-aldosterone system in kidney injury and hypertension. Genetic and environmental factors, particularly in African American populations, influence susceptibility to hypertensive renal damage. Therapies targeting oxidative stress and inflammation show promise in managing hypertension and chronic kidney disease. The study emphasizes the importance of effective blood pressure management and the need to address oxidative stress to prevent renal damage and disease progression. [Extracted from the article]

The patent application by Joel M. Friedman focuses on a transdermal delivery formulation for therapeutic agents targeting diseases associated with elevated CD38 levels and decreased NAD+ levels. The formulation aims to enhance NAD+ levels, promote sirtuin activity, and reduce inflammation by targeting CD38 overproduction. The application discusses the potential benefits of the formulation in treating various conditions, including cardiovascular diseases, inflammatory conditions, and age-related decline in physical and cognitive function. The formulation includes curcuminoids, senolytic flavonoids, polyols, and fatty acids for transdermal delivery, bypassing the gut and liver for effective administration. [Extracted from the article]

A study conducted in Lagos, Nigeria, focused on assessing the levels of various compounds in individuals with hypertension, including serum calcium, parathyroid hormone, vitamin D, renin, angiotensin II, angiotensin I converting enzyme, and aldosterone. The study found that hypertensive individuals had higher levels of parathyroid hormone, renin, angiotensin II, angiotensin I converting enzyme, and aldosterone, but lower levels of vitamin D compared to the control group. The research concluded that abnormalities in these hormones and calcium levels were associated with the pathophysiology of hypertension. For more information, readers can refer to the study titled "Assessment of Parathyroid Hormone, Vitamin D, Calcium, and Renin-angiotensin-aldosterone System in Nigerians With Hypertension." [Extracted from the article]

Researchers at Shandong University in Qingdao, China, conducted a study on the role of long non-coding RNA (LncRNA) CCAT2 in cardiac hypertrophy (CH) progression. The study found that silencing CCAT2 reduced cardiomyocyte surface area, alleviated cardiac fibrosis, and decreased certain protein levels associated with CH in mouse models. The research suggests that CCAT2 silencing may be a promising therapeutic target for CH by inactivating the Wnt/b-catenin signaling pathway. The study was supported by the Natural Science Foundation of Hubei Science and Technology Department. [Extracted from the article]

Researchers from the Department of Nephrology in Shanghai, China, have published a study on the effects of the Bushen Huoxue formula in protecting against renal fibrosis and pyroptosis in chronic kidney disease. The study utilized rat models and in vitro cell models to demonstrate that the formula inhibited renal fibrosis, oxidative stress, and NLRP3 inflammasome activation. The research concluded that the Bushen Huoxue formula reduced renal fibrosis and pyroptosis by inhibiting ROS/NLRP3-mediated inflammasome activation. The study was funded by the National Natural Science Foundation and the Summit Discipline of Clinical Traditional Chinese Medicine in The Pudong New Area of Shanghai. [Extracted from the article]